Please check your internet connection and try again.
# Hyoscine Butylbromide (Buscopan)
## Overview
A quaternary ammonium antimuscarinic agent. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier, resulting in minimal central nervous system effects. It acts as a peripheral antispasmodic on the smooth muscle of the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Spasms of the gastrointestinal tract (e.g., irritable bowel syndrome).
* Biliary colic.
* Renal colic.
* Diagnostic procedures (e.g., endoscopy or radiology to reduce motility).
## Adult Dosing
* **Oral:** 10–20 mg three to four times daily. Maximum: 80 mg/day.
* **Intramuscular (IM)/Intravenous (IV):** 20 mg as a single dose; may repeat after 30 minutes if necessary. Maximum: 100 mg/day.
* *Note: IV administration should be performed slowly.*
## Pediatric Dosing
* **Children 6–12 years:** 10 mg (one tablet) three times daily.
* **Under 6 years:** Not routinely recommended; consult local pediatric formulary as practice varies.
* **Parenteral:** Dosing is weight-based (typically 0.2–0.3 mg/kg); consult local hospital protocol for specific pediatric emergency dosing.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal standardized adjustment, but use with caution due to systemic accumulation risk in severe organ failure.
* **Elderly:** Use lower starting doses and monitor for cardiovascular or urinary retention side effects.
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Mechanical intestinal obstruction (e.g., paralytic ileus).
* Megacolon.
* Narrow-angle glaucoma.
* Tachycardia/Tachyarrhythmia.
* Prostatic hypertrophy with urinary retention.
## Adverse Effects
* **Common:** Dry mouth, visual accommodation disturbances (blurred vision), tachycardia, constipation, and dizziness.
* **Serious:** Anaphylaxis (rare), urinary retention, and angle-closure glaucoma (triggered in susceptible patients).
## Key Drug Interactions
* **Anticholinergics:** Additive effects (e.g., antihistamines, tricyclic antidepressants, antipsychotics) increase risk of dry mouth, urinary retention, and confusion.
* **Dopamine Antagonists:** Concomitant use (e.g., metoclopramide) may result in mutual antagonism of GI motility effects.
* **Tachycardic Agents:** May increase the heart rate effect of beta-adrenergic agents.
## Monitoring
* Monitor heart rate (risk of tachycardia).
* Assess for residual urine/urinary retention.
* Monitor GI symptoms to evaluate treatment efficacy.
## Clinical Pearls
* **Vascular Effect:** IV administration may cause a transient tachycardia; monitor patients closely, especially those with pre-existing cardiovascular conditions.
* **Ocular Safety:** Caution patients about the potential for transient blurred vision; avoid operating machinery until vision clears.
* **Systemic Absorption:** Poor oral bioavailability (~8%); therapeutic effect relies on local action in the gut versus systemic absorption.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug information, protocols, and availability can vary by region and clinical context. Always verify specific dosing, safety precautions, and prescribing information via your institution’s current formulary, local clinical guidelines, or the manufacturer’s official package insert before administration.
